Moxifloxacin
Moxifloxacin is an 8-methoxy fluoroquinolone - a subset of the quinolone class of antibiotics. Developed and marketed by Bayer HealthCare AG as Avelox, moxifloxacin was approved to treat several acute respiratory and uncomplicated skin and soft tissue infections. It is widely used in countries all around the world. Though it is sometimes used as a second-line TB drug, it does not have regulatory approval for use against TB or MDR-TB, although it was studied in several late-stage trials.
Moxifloxacin acts by inhibiting an enzyme called DNA gyrase, which is essential for bacterial survival. At the same time, moxifloxacin has little interaction with the cytochrome P450 enzyme system, which is heavily involved in the metabolism of some of the antiretroviral drugs (ARVs) used to treat HIV/AIDS. Therefore, moxifloxacin is an ARV-friendly TB drug candidate.
Peer-reviewed publications
- Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis
- Moxifloxacin-containing Regimens of Reduced Duration Produce a Stable Cure in Murine Tuberculosis
- 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial
- Lack of Pharmacokinetic Interaction between Moxifloxacin, a Novel 8-Methoxyfluoroquinolone, and Theophylline
- In Vitro Activity of Four Fluoroquinolones Against Mycobacterium Tuberculosis
- Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis
- Sterilizing Activities of Fluoroquinolones against Rifampin-Tolerant Populations of Mycobacterium tuberculosis
- The Bactericidal Activity of Moxifloxacin in Patients with Pulmonary Tuberculosis
- Early Bactericidal Activity of Moxifloxacin in Treatment of Pulmonary Tuberculosis: a Prospective, Randomized Study
- Moxifloxacin versus Ethambutol in the First 2 Months of Treatment for Pulmonary Tuberculosis
- Fluoroquinolones for treating tuberculosis
- Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial
- Substitution of Moxifloxacin for Isoniazid during Intensive Phase Treatment of Pulmonary Tuberculosis
- Adding moxifloxacin is associated with a shorter time to culture conversion in pulmonary tuberculosis
Clinical Trials
- Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With (J-M-Pa-Z)
- Moxifloxacin As Part of a Multi-Drug Regimen For Tuberculosis
- TBTC Study 28: Moxifloxacin Versus Isoniazid for TB Treatment
- TBTC Study 27/28 PK: Moxifloxacin Pharmacokinetics During TB Treatment
- Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers
- Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis
- Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis